RegeNovar: A phase I/II study of ubamatamab plus carboplatin, paclitaxel, and bevacizumab as salvage therapy in ovarian cancer with poor response to first-line chemotherapy.

B You, C Lebreton, F Subtil, A Carrot, JS Frenel, L Bengrine-Lefevre, …